LEXARIA BIOSCIENCE CORP. Operating Lease Cost
LEXARIA BIOSCIENCE CORP. (LEXX) reported Operating Lease Cost of $84.42 thousand for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. operating lease, cost for the quarter ending 2026-05-31 was -$7.60K.
- LEXARIA BIOSCIENCE CORP. operating lease, cost for the quarter ending 2026-02-28 was -$7.47K.
- LEXARIA BIOSCIENCE CORP. operating lease, cost for the quarter ending 2025-11-30 was $99.48K, a 22.29% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. operating lease, cost for the quarter ending 2025-08-31 was -$7.20K.
- LEXARIA BIOSCIENCE CORP. operating lease, cost for fiscal 2024 was $134.84K, a 19.47% decline from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. operating lease, cost for fiscal 2023 was $167.45K.
- LEXARIA BIOSCIENCE CORP. operating lease, cost for fiscal 2020 was $126.92K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$7.60K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-07-13 | -$15.07K derived: sum of 2 quarters · filed 2026-07-13 | $84.42K 10-Q · filed 2026-07-13 | $77.22K derived: sum of 4 quarters · filed 2026-07-13 |
| 2026-02-28 | -$7.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-13 | $92.02K 10-Q · filed 2026-04-13 | $84.82K derived: sum of 3 quarters · filed 2026-07-13 | $77.75K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-11-30 | $99.48K 10-Q · filed 2026-01-13 | $92.29K derived: sum of 2 quarters · filed 2026-07-13 | $85.22K derived: sum of 3 quarters · filed 2026-07-13 | $78.28K derived: sum of 4 quarters · filed 2026-07-13 |
| 2025-08-31 | -$7.20K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-13 | -$14.27K derived: sum of 2 quarters · filed 2026-07-13 | -$21.21K derived: sum of 3 quarters · filed 2026-07-13 | $106.82K 10-Q · filed 2026-07-13 |
| 2025-05-31 | -$7.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-07-14 | -$14.01K derived: sum of 2 quarters · filed 2025-07-14 | $114.02K 10-Q · filed 2025-07-14 | $92.29K derived: sum of 4 quarters · filed 2025-11-28 |
| 2025-02-28 | -$6.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-04-14 | $121.08K 10-Q · filed 2025-04-14 | $99.36K derived: sum of 3 quarters · filed 2025-11-28 | $99.36K derived: sum of 4 quarters · filed 2025-11-28 |
| 2024-11-30 | $128.03K 10-Q · filed 2025-01-10 | $106.30K derived: sum of 2 quarters · filed 2025-11-28 | $106.30K derived: sum of 3 quarters · filed 2025-11-28 | $106.30K derived: sum of 4 quarters · filed 2025-11-28 |
| 2024-08-31 | -$21.72K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | -$21.72K derived: sum of 2 quarters · filed 2025-11-28 | -$21.72K derived: sum of 3 quarters · filed 2025-11-28 | $134.84K 10-K · filed 2025-11-28 |
| 2024-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-07-12 | $0.00 derived: sum of 2 quarters · filed 2024-07-12 | $156.56K 10-Q · filed 2024-07-12 | |
| 2024-02-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-04-09 | $156.56K 10-Q · filed 2024-04-09 | ||
| 2023-11-30 | $156.56K 10-Q · filed 2024-01-12 | |||
| 2023-08-31 | $167.45K 10-K · filed 2024-11-26 | |||
| 2022-11-30 | $167.45K 10-Q · filed 2024-01-12 | |||
| 2021-05-31 | $0.00 10-Q · filed 2021-07-15 | |||
| 2020-11-30 | $118.19K 10-Q · filed 2021-01-14 | |||
| 2020-08-31 | $126.92K 10-K · filed 2020-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |